GlassScriptPhysician profile
Donald Mccarren
NPI 1255385662
$49,917.19
in general payments reported to CMS, 2019-2025
64 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,621 · 2020: $1,766 · 2021: $2,008 · 2022: $3,680 · 2023: $14K · 2024: $16K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $9,935 · Consulting Fee: $7,905 · Travel and Lodging: $2,167 · Education: $14.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,820.00 |
| Food and Beverage | $9,935.21 |
| Consulting Fee | $7,905.00 |
| Travel and Lodging | $2,167.35 |
| Education | $14.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20,593.95 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Biogen, INC. | $6,230.68 | 2019-2025 | Vumerity, Tysabri, Aduhelm |
| Corium, LLC | $5,457.86 | 2022-2023 | Azstarys, Adlarity |
| Eisai INC. | $4,945.80 | 2021-2025 | |
| Ucb, INC. | $1,331.89 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Ge Healthcare | $1,024.68 | 2020-2025 | |
| Abbvie INC. | $990.19 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $698.97 | 2022-2024 | Onpattro, Amvuttra |
| Argenx US, INC. | $574.55 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurocrine Biosciences, INC. | $572.65 | 2019-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $524.63 | 2019-2025 | Mavenclad |
| Mdd US Operations, LLC | $482.71 | 2023-2025 | Gocovri, Gocovri |
| Amgen INC. | $411.96 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $405.05 | 2019-2024 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $402.36 | 2021-2023 | Ponvory |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Mccarren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.